Patient Support Services Contact Us

Our Pipeline

Addressing Important Unmet Needs

At Coherus, we put patients first. We're dedicated to improving lives by expanding access to biologics. Our robust pipeline is bringing high-value treatments to patients in need. We have the assets, expertise, and insights to bring high-quality products to patients around the world.

Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
ONCOLOGY PIPELINE
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3
/BLA Enabling
ApprovedStatus
UDENYCA™pegfilgrastim
biosimilar

Approved by the US Food and Drug Administration and European Commission

Anti-TNF Pipeline
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
CHS-1420adalimumab
biosimilar

Phase 3 clinical studies in psoriasis completed

Focus on securing competitive launch in US market

CHS-0214etanercept
biosimilar

Phase 3 clinical studies in psoriasis and RA completed

Ophthalmology Pipeline
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
CHS-3351ranibizumab
biosimilar

Pre-clinical development

CHS-2020aflibercept
biosimilar

Pre-clinical development

METABOLIC PIPELINE
Product/
Candidate
DescriptionPre-ClinicalPhase 1/2Phase 3/
BLA Enabling
ApprovedStatus
CHS-131 Selective PPAR-gamma modulator

Initiating Phase 2 studies in NASH

Completed Phase 2 studies in Type II diabetes and multiple sclerosis

CHS-5217
trastuzumab (Avastin)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-0214
etanercept (Enbrel)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-1420
adalimumab (HUMIRA)
ORIGINATOR APPROVED INDICATIONSstatustiming
CHS-3551
ranibizumab (Lucentis)
ORIGINATOR APPROVED INDICATIONSstatustiming